Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens.
The aim of the study was to compare the effects of continuous oral estrogen/progestin therapy to the effects of transdermal estrogen therapy combined with cyclic oral progestin on the properties of LDL particles. Eighty postmenopausal women were randomly allocated to receive either oral (continuous 17-beta-estradiol 2 mg and norethisterone acetate 1 mg per day, E2/NETA) or transdermal therapy (patches delivering continuous 17-beta-estradiol, E2, 0.05 mg/day with sequential oral medroxyprogesterone acetate, MPA, 10 mg/day for 12 days/cycle). The groups had similar mean values and ranges of age, BMI and postmenopausal status. The blood samples were taken at baseline, and twice at 1 year before and after MPA administration. LDL particle size distribution was determined by gradient gel electrophoresis and LDL was isolated by sequential ultracentrifugation for compositional analyses. Concentrations of total LDL mass, LDL cholesterol and LDL protein decreased in the oral treatment group (p < 0.01, p < 0.001 and p < 0.01, respectively), whereas they remained unchanged during the transdermal therapy. Particle size of the major LDL peak remained unchanged during both transdermal and oral therapies. HDL cholesterol concentration decreased significantly in both treatment groups (p < 0.001 for both). Serum triglyceride and HDL cholesterol concentrations were the strongest determinants of LDL particle size ( r = -0.50 and r = 0.54, respectively, p < 0.001 for both). The cholesteryl esters and free cholesterol content of the LDL particles decreased in the oral treatment group (p < 0.05). Phospholipid content of LDL increased in both groups receiving either oral or transdermal therapy (p < 0.01 for both). In conclusion, oral administration of 17-beta-estradiol and norethisterone acetate caused a decrease in LDL mass by decreasing the number and cholesterol content of LDL particles. The concomitant decrease of HDL cholesterol by progestins may partly negate this beneficial effect of LDL lowering.
Lahdenperä
S
S
Department of Medicine, University of Helsinki, Finland.
Puolakka
J
J
Pyörälä
T
T
Luotola
H
H
Taskinen
M R
MR
D000279:Administration, Cutaneous; D000284:Administration, Oral; D001794:Blood Pressure; D015992:Body Mass Index; D004338:Drug Combinations; D004591:Electrophoresis, Polyacrylamide Gel; D004958:Estradiol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008875:Middle Aged; D009640:Norethindrone / Q000627:therapeutic use*; D017698:Postmenopause / Q000097:blood* / Q000187:drug effects; D045167:Progesterone Congeners / Q000627:therapeutic use*
D004338:Drug Combinations; D008077:Lipoproteins, LDL; D045167:Progesterone Congeners; D004958:Estradiol; D008525:Medroxyprogesterone; D009640:Norethindrone